Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma

BMC Cancer

Xiao-dan Zhong¹  Yu-Tong Zhang¹  Jian Chang¹  Yan-li Gao² 

[1]Department of Pediatric Oncology, The First Hospital of Jilin University, 130021, Changchun, Jilin, China

[2]Department of Pediatric Ultrasound, The First Hospital of Jilin University, Changchun, Jilin, China

关键词: Pleural effusion;    Ascites;    Pericardial effusion;    Interleukin-2;    Pediatric cancer;   

DOI  :  10.1186/s12885-021-09041-7

来源: Springer

【 摘 要 】

BackgroundCurrently, no available coherent management protocol exists for pediatric cancers associated with pleural effusion, ascites, and pericardial effusion. This study aimed to retrospectively present our experience in treating pediatric cancer patients with pleural effusion, ascites, and pericardial effusion using interleukin-2 (IL-2) and dexamethasone (DEX) intracavitary injections.MethodsBetween January 1st, 2008 and December 31st, 2020, medical reports of patients diagnosed with solid tumors or lymphoma were checked to identify patients diagnosed with > 2 cm pleural effusion, and/or more than grade 1 ascites, and/or more than small pericardial effusion. Patients diagnosed with effusions and treated with IL-2 and DEX were identified as being in the effusion group. Meanwhile, patients with the same primary tumors and effusions but did not receive interleukin 2 and DEX injection were reviewed and classified as the control group.ResultsForty patients with solid tumors and 66 patients with lymphoma were further diagnosed with pleural effusion, ascites, or pericardial effusion. A total of 85 patients received IL-2 and DEX injection while the remaining 21 did not. The Kaplan Meier analysis revealed a significant difference between the two groups, with p < 0.01 for event free survival (EFS) and p < 0.01 for overall survival (OS), both of which had p < 0.01. Hazard ratio was found to be 0.344 for OS and 0.352 for EFS.ConclusionsThis retrospective study illustrates that thoracic, intraperitoneal, or pericardial intracavitary injection of DEX plus IL-2 can be an effective and safe treatment for pediatric cancers with pleural effusion, ascites, and pericardial effusion.

【 授权许可】

CC BY